Who founded Dracenpharma?

Dracenpharma was founded by Robert Wild in 2016.

Who are Dracenpharma's investors?

Dracenpharma's investors include Biotech Investments S.R.O, OUP (Osage University Partners), Deerfield Management Company.

How much funding has Dracenpharma raised?

Dracenpharma has disclosed $19.4M raised across 3 rounds.

Where is Dracenpharma headquartered?

Dracenpharma is headquartered in Baltimore, US.

Dracenpharma

Baltimore, US · Founded 2016 · 3 known investors

Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment. Its lead candidate, sirpiglenastat (DRP-104), is in clinical trials for advanced solid tumors including KEAP1/NFE2L2-altered non-small cell lung cancer.

Biotech Healthtech

Founders & leadership

Dracenpharma was founded in 2016 by Robert Wild.

Robert WildCo-founder & Chief Scientific Officer

Thomas M. EstokChief Executive Officer, President and Treasurer

Drew Pardoll, M.D., Ph.D.Named on SEC filing

Asher RubinSecretary

Board

Jonathan LeffBoard directorPartner at Deerfield Management Company

Robert JacksonBoard director

Investors · 3

Biotech Investments S.R.OPrague

OUP (Osage University Partners)Bala Cynwyd · $1M – $20M

Deerfield Management CompanyreportedNew Yorkvia Jonathan Leff · board

Reported raises · per SEC filings

Form D private placements

$19.4M disclosed across 3 rounds · 2018–2023

▶$2.3MraisedAug 2023 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Asher RubinExecutive Officer
Drew Pardoll, M.D., Ph.D.Director
Dennis M. BilskiExecutive Officer
Jonathan LeffDirector

Offering amount: $2.8M
Amount sold: $2.3M
Minimum investment: $2.7K
Proceeds to insiders: $45K
First sale: Jun 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$8.6MraisedNov 2021 · 8 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Asher RubinExecutive Officer
Dennis BilskiExecutive Officer
Thomas M. EstokExecutive Officer, Director
Drew Pardoll, M.D., Ph.D.Director
Jonathan LeffDirector

Offering amount: $17M
Amount sold: $8.6M
First sale: Nov 2021
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$8.5MraisedJan 2018 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Drew Pardoll, M.D., Ph.D.Director
Thomas M. EstokExecutive Officer, Director
Jonathan LeffDirector
Asher RubinExecutive Officer
Robert JacksonDirector

Offering amount: $40.5M
Amount sold: $8.5M
First sale: Jan 2018
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Dracenpharma for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Dracenpharma do?: Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment. Its lead candidate, sirpiglenastat (DRP-104), is in clinical trials for advanced solid tumors including KEAP1/NFE2L2-altered non-small cell lung cancer.
Who founded Dracenpharma?: Dracenpharma was founded by Robert Wild in 2016.
Who are Dracenpharma's investors?: Dracenpharma's investors include Biotech Investments S.R.O, OUP (Osage University Partners), Deerfield Management Company.
How much funding has Dracenpharma raised?: Dracenpharma has disclosed $19.4M raised across 3 rounds.
Where is Dracenpharma headquartered?: Dracenpharma is headquartered in Baltimore, US.